Figure 5.

Biodistribution of anti-ICAM and anti-ICAM nanocarriers in the GI tract. Mice were gavaged with PBS containing ¹²⁵I-anti-ICAM vs ¹²⁵I-IgG (A) or ¹²⁵I-anti-ICAM NCs vs ¹²⁵I-IgG NCs (B), and ¹²⁵Iodine biodistribution in the stomach, duodenum, and distal GI regions (encompassing jejunum, ileum, cecum, and colon) was assessed one hour later as described in Figure 1. A comparison of the biodistribution of ¹²⁵I-anti-ICAM vs ¹²⁵I-anti-ICAM NCs is shown in (C).

Notes: Results are expressed as % ID. Data are mean ± SEM, (n ≥ 3). (A) and (B) *P < 0.05; **P < 0.005 between nontargeting IgG and ICAM-targeting groups. (C) *P < 0.05 between anti-ICAM free antibody and anti-ICAM NCs.

Abbreviations: ICAM, intercellular adhesion molecule; GI, gastrointestinal; PBS, phosphate-buffered saline; NC, nanocarrier; % ID, percentage of the total injected dose; SEM, standard error of the mean.